Aspen Pharmacare Holdings Toekomstige groei
Future criteriumcontroles 4/6
Aspen Pharmacare Holdings zal naar verwachting groeien in winst en omzet met respectievelijk 22.6% en 7.6% per jaar. De winst per aandeel zal naar verwachting groeien met 21% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 9.7% zijn.
Belangrijke informatie
22.6%
Groei van de winst
21.0%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 19.4% |
| Inkomstengroei | 7.6% |
| Toekomstig rendement op eigen vermogen | 9.7% |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 04 Nov 2024 |
Recente toekomstige groei-updates
Recent updates
Aspen Pharmacare Holdings' (JSE:APN) Conservative Accounting Might Explain Soft Earnings
Oct 10
Here's Why Aspen Pharmacare Holdings (JSE:APN) Has A Meaningful Debt Burden
Oct 01Aspen Pharmacare Holdings (JSE:APN) Has Announced That It Will Be Increasing Its Dividend To ZAR3.59
Sep 10We Think Aspen Pharmacare Holdings (JSE:APN) Can Stay On Top Of Its Debt
May 08Aspen Pharmacare Holdings Limited's (JSE:APN) P/E Still Appears To Be Reasonable
Mar 05Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet
Dec 22Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Is Looking A Bit Stretched At The Moment
Dec 01Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet
Mar 31With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Makes An Interesting Case
Jan 11These 4 Measures Indicate That Aspen Pharmacare Holdings (JSE:APN) Is Using Debt Reasonably Well
Oct 22We Ran A Stock Scan For Earnings Growth And Aspen Pharmacare Holdings (JSE:APN) Passed With Ease
Oct 06Aspen Pharmacare Holdings' (JSE:APN) Upcoming Dividend Will Be Larger Than Last Year's
Sep 21Aspen Pharmacare Holdings Limited (JSE:APN) Analysts Just Cut Their EPS Forecasts Substantially
Sep 08Aspen Pharmacare Holdings (JSE:APN) Is Increasing Its Dividend To ZAR3.26
Sep 07Here's Why We Think Aspen Pharmacare Holdings (JSE:APN) Might Deserve Your Attention Today
Jun 15Aspen Pharmacare Holdings (JSE:APN) Seems To Use Debt Quite Sensibly
Apr 02With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Is Interesting
Mar 16An Intrinsic Calculation For Aspen Pharmacare Holdings Limited (JSE:APN) Suggests It's 33% Undervalued
Mar 02Is Aspen Pharmacare Holdings (JSE:APN) A Risky Investment?
Dec 23Shareholders Will Probably Not Have Any Issues With Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation
Dec 02We Think Aspen Pharmacare Holdings' (JSE:APN) Robust Earnings Are Conservative
Oct 11After Leaping 42% Aspen Pharmacare Holdings Limited (JSE:APN) Shares Are Not Flying Under The Radar
Sep 30Aspen Pharmacare Holdings Limited (JSE:APN) Looks Just Right With A 42% Price Jump
Sep 30Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 6/30/2027 | 55,952 | 8,756 | 6,975 | 14,632 | 3 |
| 6/30/2026 | 52,710 | 8,561 | 6,321 | 13,606 | 5 |
| 6/30/2025 | 48,528 | 6,487 | 4,589 | 12,016 | 5 |
| 6/30/2024 | 44,706 | 4,404 | 692 | 6,225 | N/A |
| 3/31/2024 | 43,703 | 4,636 | 1,023 | 6,248 | N/A |
| 12/31/2023 | 42,700 | 4,868 | 1,354 | 6,271 | N/A |
| 9/30/2023 | 41,705 | 5,048 | 1,849 | 5,896 | N/A |
| 6/30/2023 | 40,709 | 5,228 | 2,343 | 5,520 | N/A |
| 3/31/2023 | 39,542 | 5,515 | 2,545 | 5,420 | N/A |
| 12/31/2022 | 38,375 | 5,802 | 2,747 | 5,320 | N/A |
| 9/30/2022 | 38,491 | 6,145 | 2,875 | 5,347 | N/A |
| 6/30/2022 | 38,606 | 6,488 | 3,002 | 5,374 | N/A |
| 3/31/2022 | 38,560 | 6,185 | 3,826 | 6,110 | N/A |
| 12/31/2021 | 38,514 | 5,881 | 4,649 | 6,846 | N/A |
| 9/30/2021 | 38,140 | 5,340 | 4,209 | 6,836 | N/A |
| 6/30/2021 | 37,766 | 4,798 | 3,769 | 6,825 | N/A |
| 3/31/2021 | 35,760 | 3,954 | 4,119 | 7,115 | N/A |
| 12/31/2020 | 36,308 | 3,782 | 4,468 | 7,405 | N/A |
| 9/30/2020 | 34,984 | 3,581 | 5,141 | 7,833 | N/A |
| 6/30/2020 | 33,659 | 3,380 | 5,814 | 8,260 | N/A |
| 3/31/2020 | 39,927 | 3,272 | 4,508 | 7,573 | N/A |
| 12/31/2019 | 33,620 | 870 | 3,202 | 6,886 | N/A |
| 9/30/2019 | 34,567 | 1,275 | 2,856 | 6,444 | N/A |
| 6/30/2019 | 35,514 | 1,679 | 2,509 | 6,002 | N/A |
| 3/31/2019 | 36,880 | 3,350 | 1,400 | 5,864 | N/A |
| 12/31/2018 | 36,683 | 4,890 | 291 | 5,726 | N/A |
| 9/30/2018 | 37,499 | 5,256 | -429 | 6,372 | N/A |
| 6/30/2018 | 38,314 | 5,621 | -1,149 | 7,017 | N/A |
| 3/31/2018 | 39,618 | 5,682 | N/A | 6,653 | N/A |
| 12/31/2017 | 40,922 | 5,743 | N/A | 6,289 | N/A |
| 9/30/2017 | 41,068 | 5,436 | N/A | 6,388 | N/A |
| 6/30/2017 | 41,213 | 5,128 | N/A | 6,487 | N/A |
| 3/31/2017 | 39,557 | 4,414 | N/A | 5,694 | N/A |
| 12/31/2016 | 37,900 | 3,700 | N/A | 4,900 | N/A |
| 9/30/2016 | 36,750 | 4,000 | N/A | 4,050 | N/A |
| 6/30/2016 | 35,600 | 4,300 | N/A | 3,200 | N/A |
| 3/31/2016 | 35,583 | 5,220 | N/A | 3,406 | N/A |
| 12/31/2015 | 35,567 | 6,140 | N/A | 3,613 | N/A |
| 9/30/2015 | 35,833 | 5,670 | N/A | 4,206 | N/A |
| 6/30/2015 | 36,100 | 5,200 | N/A | 4,800 | N/A |
| 3/31/2015 | 35,836 | 5,369 | N/A | 5,074 | N/A |
| 12/31/2014 | 35,572 | 5,537 | N/A | 5,347 | N/A |
| 9/30/2014 | 32,544 | 5,272 | N/A | 4,592 | N/A |
| 6/30/2014 | 29,515 | 5,008 | N/A | 3,836 | N/A |
| 3/31/2014 | 25,901 | 4,388 | N/A | 3,841 | N/A |
| 12/31/2013 | 22,287 | 3,768 | N/A | 3,847 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei APN ( 22.6% per jaar) ligt boven de spaarquote ( 9.7% ).
Winst versus markt: De winst van APN ( 22.6% per jaar) zal naar verwachting sneller groeien dan de ZA markt ( 21.6% per jaar).
Hoge groeiwinsten: De winst van APN zal naar verwachting de komende 3 jaar aanzienlijk groeien.
Omzet versus markt: De omzet van APN ( 7.6% per jaar) zal naar verwachting sneller groeien dan de markt ZA ( 3.5% per jaar).
Hoge groei-inkomsten: De omzet van APN ( 7.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen APN zal naar verwachting over 3 jaar laag zijn ( 9.7 %).